Cargando…
The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
BACKGROUND: Gastric cancer is a malignant tumor originating from the gastric mucosal epithelium, ranking fourth in the incidence of male malignant tumors and third in mortality rate. The aim of this study is to investigate the efficacy and adverse reactions of DCF and FOLFOXs regimens in the treatme...
Autores principales: | Chen, Minxue, Fan, Yong, Zhao, Zhiqiang, Nie, Yuanhua, Ma, Fulin, Wang, Xingang, Wei, Qiuya, Wang, Yuebin, Kang, Boxiong, Liu, Yongyong, Chen, Hao, Wang, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797895/ https://www.ncbi.nlm.nih.gov/pubmed/35117794 http://dx.doi.org/10.21037/tcr-19-2564 |
Ejemplares similares
-
Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
por: Salehifar, Ebrahim, et al.
Publicado: (2019) -
The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer
por: Acikgoz, Yusuf, et al.
Publicado: (2021) -
Anillin is a prognostic factor and is correlated with genovariation in pancreatic cancer based on databases analysis
por: Nie, Yuanhua, et al.
Publicado: (2021) -
Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east
por: Farrokhi, Pegah, et al.
Publicado: (2022) -
DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study
por: FENG, ZENG-LI, et al.
Publicado: (2015)